§ LICENSING & PIPELINE—Q1 2026 READOUT
Licensing & Pipeline.
We license clinical-stage assets and leverage our tech-driven platform to develop them, generating more value per program by reaching the next value inflection point in the development lifecycle faster and more efficiently. By developing our portfolio assets faster than industry norms, we can take more shots on goal, increasing the likelihood of success for us and our partners.
Active programs
11
In Phase 1
4
Partnered
8/11
Active portfolio.
Filter by indication. Each program has a dedicated data room available to partners under MNDA — request access via the partnerships team.
NameMechanismIndication
DiscoveryOptimizationIND-EnablingPhase 1Phase 2
UNO-101DNA aptamer (Ds artificial base-pair chemistry)Immunodermatology→
UNO-201Oncolytic membrane-disrupting peptideNeoadjuvant melanoma→
UNO-301Umbilical cord MSC cell therapyPost-HSCT pulmonary complications→
UNO-401Small-molecule ferroptosis inducerSolid tumour oncology→
UNO-501iPSC-derived nephron progenitor cell therapyEnd-stage renal disease→
UNO-601Genome-edited iPSC cell therapy (CRISPR-Cas3)Recurrent glioblastoma→
/ 01 Discovery
/ 02 Optimization
/ 03 IND-Enabling
/ 04 Phase 1
/ 05 Phase 2
Development Candidate Declared